SCHEMBL905344

SCHEMBL905344

CNC(=O)c1cnc(Cl)cc1-c1ccccc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPBAR1 Q8TDU6 3/20 0.50
POLQ O75417 3/20 0.46
PIK3CD O00329 3/20 0.42
NPC1 O15118 1/20 0.40
ALOX15 P16050 1/20 0.40
HTT P42858 1/20 0.40
RAB9A P51151 1/20 0.40
NUDT1 P36639 1/20 0.40
KMT2A Q03164 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
ALOX5AP P20292 1/20 0.38
FEN1 P39748 1/20 0.38
CNR1 P21554 1/20 0.38
JAK2 O60674 1/20 0.38
JAK1 P23458 1/20 0.38
TYK2 P29597 1/20 0.38
JAK3 P52333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27567270 0.87 PAK1 (0.43) NUDT1ALOX5APFEN1CNR1JAK2
SCHEMBL7110261 0.85 GPBAR1 (0.47) GPBAR1POLQPIK3CDNPC1ALOX15
SCHEMBL7112604 0.85 L3MBTL1 (0.53) HTTKMT2AL3MBTL1CYP1A2GAA
SCHEMBL7112402 0.84 GPBAR1 (0.53) GPBAR1POLQNPC1RAB9AKMT2A
SCHEMBL14576072 0.84 POLQ (0.47) POLQNUDT1KMT2AL3MBTL1ALOX5AP
SCHEMBL28743630 0.83 POLQ (0.46) POLQPIK3CDNPC1ALOX15RAB9A
SCHEMBL7111091 0.83 GPBAR1 (0.52) GPBAR1POLQPIK3CDJAK2JAK1
SCHEMBL27549842 0.81 POLQ (0.47) POLQNPC1ALOX15HTTRAB9A
SCHEMBL27521745 0.81 POLQ (0.44) GPBAR1POLQPIK3CDALOX15KMT2A
SCHEMBL27547325 0.80 POLQ (0.43) GPBAR1POLQPIK3CDKMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1394150-B1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2011-01-19 EP disclosed
EP-1303490-B1 N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2008-07-09 EP disclosed
CN-1293056-C 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2007-01-03 CN disclosed
EP-1309559-B1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2006-06-07 EP disclosed
EP-1305319-B1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2006-04-05 EP disclosed
US-6897226-B2 NK-1 receptor active amine oxide prodrugs HOFFMANN-LA ROCHE INC. (US) 2005-05-24 US disclosed
CN-1610670-A 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2005-04-27 CN disclosed
CN-1192032-C 4-phenyl-pyridine derivatives as neurokinin-1 receptor antagonists HOFFMANN LA ROCHE (CH) 2005-03-09 CN disclosed
CN-1178917-C N-oxides of 4-phenyl-pyridine derivatives as NK1 receptor antagonist prodrugs - 2004-12-08 CN disclosed
US-6806370-B2 NEUROKININ-1 RECEPTOR ANTAGONISTS ARE FURTHER USEFUL FOR THE TREATMENT OF MOTION SICKNESS AND FOR TREATMENT INDUCED VOMITING HOFFMANN-LA ROCHE INC. 2004-10-19 US disclosed
US-20020045642-A1 NK-1 receptor active amine oxide prodrugs HOFFMANN-LA ROCHE INC. 2002-04-18 US disclosed
US-20020040040-A1 Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors F. HOFFMAN-LA ROCHE AG (CH) 2002-04-04 US disclosed
US-20020038030-A1 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors F.HOFFMANN-LA ROCHE AG (CH) 2002-03-28 US disclosed
WO-2002016324-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-02-28 WO disclosed
WO-2002008232-A1 4-PHENYL-PYRIDINE DERIVATIVES AS NEUROKININ-1 RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2002-01-31 WO disclosed
WO-2002006236-A1 N-OXIDES AS NK1 RECEPTOR ANTAGONIST PRODRUGS OF 4-PHENYL-PYRIDINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2002-01-24 WO disclosed
US-6303790-B1 REACTING SUBSTITUTED NICOTINAMIDE WITH GRIGNARD REAGENT, OXIDIZING PRODUCT, REACTING WITH HALO-SUBSTITUTED AROMATIC COMPOUND HOFFMAN-LA ROCHE INC. 2001-10-16 US disclosed
US-6297375-B1 4-phenyl-pyridine derivatives HOFFMANN-LA ROCHE INC. 2001-10-02 US disclosed
EP-1103546-A1 Process for preparation of pyridine derivatives F. HOFFMANN-LA ROCHE AG (CH) 2001-05-30 EP disclosed
EP-1035115-A1 4-Phenylpyridine derivatives and their use as NK-1 receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2000-09-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020040040-A1 Substituted 4-phenyl-pyridine compounds with activity as antagonists of neurokinin 1 receptors NPSR1, NTSR1, NTSR2 GPBAR1 430/4885POLQ 4831/4885PIK3CD 2985/4885
US-20020045642-A1 NK-1 receptor active amine oxide prodrugs TACR1, BDKRB1, NPSR1 GPBAR1 145/4885POLQ 4639/4885PIK3CD 2022/4885
US-20020038030-A1 Heteroaromatic substituted amides with antagonistic activity to neurokinin 1 receptors TACR1, NPSR1, TACR2 GPBAR1 539/4885POLQ 4530/4885PIK3CD 2887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.